Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: J Leukoc Biol. 2022 Jun 13;112(4):845–859. doi: 10.1002/JLB.1MA0422-518RR

Fig. 2. rMos are potent suppressors of T cells.

Fig. 2

a-c, The degree of suppression, at the indicated effector:T cell ratio, of CD8 (left) and CD4 (right) T cell proliferation by purified WT or Rel−/− CD11b+CCR2+ cells (rMos) and CD11b+CCR2− cells from i) cytokine-treated bone marrow cultures of naïve mice (a, n=3 /group); ii) mice that had similarly sized B16F10 tumors (b, n=3 /group); or iii) cytokine-treated bone marrow cultures of naïve mice, with or without R96A (c, n=3 /group), (*, P<0.05; **, P<0.01; ***, P<0.001).

d, e, Transmigration of CD11b+CCR2+ and CD11b+CCR2− cells, isolated as described in a (d) and c (e), (*, P<0.05; **, P<0.01).

Statistical significance was determined by two-way ANOVA with Tukey post-hoc test (a-c) and one-way ANOVA with Tukey post-hoc test (d,e). For all panels, technical replicates of pooled samples (5 mice per group) were tested; data are presented as means ± s.e.m., and experiments were repeated 2 times independently with similar results; data from one representative experiment are shown.